CR20130006A - Composición de péptidos terapéuticos y método - Google Patents

Composición de péptidos terapéuticos y método

Info

Publication number
CR20130006A
CR20130006A CR20130006A CR20130006A CR20130006A CR 20130006 A CR20130006 A CR 20130006A CR 20130006 A CR20130006 A CR 20130006A CR 20130006 A CR20130006 A CR 20130006A CR 20130006 A CR20130006 A CR 20130006A
Authority
CR
Costa Rica
Prior art keywords
composition
therapeutic peptides
therapeutic peptide
therapeutic
insulin
Prior art date
Application number
CR20130006A
Other languages
English (en)
Inventor
Bassam B Damaj
Richard Martin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of CR20130006A publication Critical patent/CR20130006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones de péptidos terapéuticos que comprenden un péptido terapéutico, tal como insulina, junto con un N,N-disustituido aminoacetato de alquilo, tal como 2-(N,N-dimetilamino) propionato de dodecilo.
CR20130006A 2010-05-04 2013-01-07 Composición de péptidos terapéuticos y método CR20130006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34381510P 2010-05-04 2010-05-04

Publications (1)

Publication Number Publication Date
CR20130006A true CR20130006A (es) 2013-06-27

Family

ID=44903936

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130006A CR20130006A (es) 2010-05-04 2013-01-07 Composición de péptidos terapéuticos y método

Country Status (16)

Country Link
US (2) US20130209393A1 (es)
EP (1) EP2566503A4 (es)
JP (1) JP2013528587A (es)
KR (1) KR20130067266A (es)
CN (1) CN102858364A (es)
AU (1) AU2011249040B2 (es)
BR (1) BR112012027886A2 (es)
CA (1) CA2797966A1 (es)
CR (1) CR20130006A (es)
IL (1) IL222425A0 (es)
MX (1) MX336037B (es)
NZ (1) NZ603091A (es)
RU (1) RU2012153175A (es)
SG (2) SG186300A1 (es)
WO (1) WO2011139370A1 (es)
ZA (1) ZA201209021B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
JP5144861B2 (ja) * 1998-07-27 2013-02-13 エミスフェアー・テクノロジーズ・インク 活性剤のデリバリーのための化合物及び組成物
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
EP1635770B1 (en) * 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
EP1663142A2 (en) * 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
WO2012097160A1 (en) * 2011-01-14 2012-07-19 Nexmed Holdings, Inc. Rectal delivery method for therapeutic peptides

Also Published As

Publication number Publication date
SG186300A1 (en) 2013-01-30
IL222425A0 (en) 2012-12-31
MX336037B (es) 2016-01-07
AU2011249040B2 (en) 2014-05-15
WO2011139370A1 (en) 2011-11-10
ZA201209021B (en) 2013-09-25
RU2012153175A (ru) 2014-06-20
US20130209393A1 (en) 2013-08-15
EP2566503A1 (en) 2013-03-13
JP2013528587A (ja) 2013-07-11
NZ603091A (en) 2014-10-31
CA2797966A1 (en) 2011-11-10
SG10201600228QA (en) 2016-03-30
BR112012027886A2 (pt) 2016-08-09
EP2566503A4 (en) 2013-10-02
AU2011249040A1 (en) 2012-11-08
MX2012012823A (es) 2013-03-05
KR20130067266A (ko) 2013-06-21
US20150265709A1 (en) 2015-09-24
CN102858364A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
BR112014030714A2 (pt) composto de lipídeo ionizável , composições , carreador de fármaco , formulação farmacêutica e método de entrega de um fármaco
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
HUE055061T2 (hu) Szivárgásgátlóval ellátott aeroszol-képzõ rendszer
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
CU20150037A7 (es) Soluciones inyectables estables exentas de conservantes de compuestos antimidriásicos y anti-inflamatorios
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CO6930364A2 (es) Composiciones farmaceúticas que comprenden 40-o-(2-hidroxi) etil - rapamicina
EA201391489A1 (ru) Композиции со сниженной вязкостью
ECSP14033284A (es) Composición herbicida que tiene actividad herbicida mejorada
CO7151499A2 (es) Formulación inyectable
MX376496B (es) Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival.
BR112013026462A2 (pt) protetor de pé
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
BR112013023575A8 (pt) novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
UY34477A (es) Composición herbicida sinérgica que contiene penoxsulam y glufosinato de amonio
BR112013019061A2 (pt) composto inibidor da caspase-2, composição farmacêutica e uso de um composto
DK2734145T3 (da) Abutment til en kunstig tandprotese
CR20130006A (es) Composición de péptidos terapéuticos y método
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.